On Nov. 29, 2023, Novavax’s partner, SK bioscience, announced that Novavax’s updated COVID-19 vaccine (NVX-CoV2601) had received Emergency Use Authorization from the Ministry of Food and Drug Safety in the Republic of Korea. Doses were available in market for use this vaccination season. In South Korea, SK bioscience and Novavax have a licensing agreement where SK bioscience has exclusive commercial rights to Novavax’s updated COVID-19 vaccine.

Novavax’s updated COVID-19 vaccine was also authorized in the U.S.,the European Union and by the World Health Organization,and is under review in other markets.